Home Blog Page 1420

AllsWell Marks Consecutive Appearances at CES: From Managed Brand PR to GEO, Advancing Brand Growth in the Generative Search Era

At CES 2026, AllsWell Announces Strategic Partnership with LEAP GEO to Help Brands Move from Exposure to AI Citations and Recommendations

LAS VEGAS, Jan. 27, 2026 /PRNewswire/ — Global brand communications and public relations consultancy AllsWell announced at the 2026 Consumer Electronics Show (CES) that it has entered into a strategic partnership with LEAP GEO, a firm specializing in Generative Engine Optimization (GEO). Through this collaboration, the two companies will integrate managed brand public relations with generative engine optimization to deliver communications solutions designed for the generative search environment, enabling outbound and overseas growth brands to move beyond traditional exposure metrics toward measurable growth in AI citations and recommendations.

AllsWell Marks Consecutive Appearances at CES: From Managed Brand PR to GEO, Advancing Brand Growth in the Generative Search Era
AllsWell Marks Consecutive Appearances at CES: From Managed Brand PR to GEO, Advancing Brand Growth in the Generative Search Era

The partnership centers on a critical question in the generative AI era: how brands are referenced, recommended, and trusted by AI-driven systems. By aligning content structure, communications execution, and ongoing optimization of citation outcomes, AllsWell and LEAP GEO aim to build a communications framework that is actionable, trackable, and continuously improvable. This collaboration represents a significant expansion of AllsWell’s capabilities in response to the rapidly evolving global communications landscape.

Consecutive CES Announcements Highlight AllsWell’s Capability Evolution

At CES 2025, AllsWell announced a strategic partnership with a New York–based public relations firm, establishing a managed PR execution model across the North American market. This model emphasized full-spectrum involvement—from communications strategy and media relations to on-the-ground execution and delivery of measurable outcomes—addressing a common challenge in cross-market communications where strategy and execution are often misaligned.

Since 2025, the widespread adoption of generative AI in information discovery, product evaluation, and decision-making has further reshaped the communications environment. Increasingly, users turn directly to generative AI systems for answers and recommendations, rather than relying solely on traditional search engines or individual media outlets.

As a result, the effectiveness of brand communications is no longer measured only by visibility or coverage. Instead, a growing emphasis is placed on whether a brand is cited, recommended, and consistently referenced by generative AI systems.

Integrating GEO into the Communications Stack to Address New Measurement Challenges

Against this backdrop, AllsWell’s announcement at CES 2026 formally incorporates GEO capabilities into its long-standing Managed Partnership Model, creating an integrated communications framework that spans:

  • Brand strategy and narrative development
  • Managed PR execution and media relations
  • Brand visibility within generative search environments
  • Sustained growth in AI citations and recommendations

LEAP GEO focuses on generative engine optimization methodologies and content engineering, helping brand information be structured and presented in ways that generative AI platforms can more effectively understand, retrieve, and cite. A core value of GEO lies in transforming AI citations—previously opaque and difficult to measure—into trackable, analyzable, and optimizable growth indicators, across multiple platforms and languages.

AllsWell’s managed partnership approach ensures that these capabilities are not applied in isolation. Instead, they are integrated with real-world communications execution, verified media exposure, and long-term relationship building, allowing brand narratives to compound into durable brand assets over time.

Collaboration Focus: Aligning Communications Execution with Citation Growth

Through this strategic partnership, AllsWell and LEAP GEO will collaborate across three primary areas:

  • Establishing PR asset standards for the AI Search era, defining content structures, information hierarchies, and evidence frameworks that are more likely to be cited by generative AI systems;
  • Delivering communications solutions centered on AI citations, with ongoing optimization of content creation, distribution, and presentation;
  • Supporting long-term growth brands, converting short-term exposure into compounding trust and recommendation assets in overseas markets.

The founder of LEAP GEO commented:

“In generative search environments, being cited by AI is becoming a critical growth variable. GEO aims to make citation growth a manageable and optimizable outcome. Partnering with AllsWell allows this capability to be systematically embedded into brand communications and media execution.”

The founder of AllsWell added:

“AllsWell has always focused on building brand communications that are authentic, credible, and verifiable. In the generative search era, brands must not only be worthy of citation, but also structurally easier to cite. Our partnership with LEAP GEO represents an important step in systemically upgrading the value of brand communications.”

About AllsWell

AllsWell is a global brand communications and public relations consultancy serving clients across North America, Europe, and the Asia-Pacific region. The firm specializes in long-term, value-driven communications strategy, media relations, and managed execution for outbound and overseas growth brands.

European Investment Bank (EIB) backs Minesto in developing an investment case for the EU’s first Tidal Energy Dragon Farm

GOTHENBURG, Sweden, Jan. 27, 2026 /PRNewswire/ — Minesto, leading ocean energy developer, has on a complementary basis been selected for in-depth investment advisory support by the European Investment Bank (EIB) under the PDA (Project Development Assistance) programme. The program offers extensive free of charge financial advisory support to a few carefully selected investment opportunities within the renewable energy sector in the EU. The Minesto investment case chosen for the programme is a 10MW Dragon Farm (tidal energy array) located at a new targeted site within EU waters. The EIB advisory support focus’s on increasing the financial attractiveness and overall quality of the investment offer, aiming to raise 25 M EUR in capital. The programme commences immediately.

Minesto has been selected by the EIB for project development assistance with a focus on investment attractiveness, targeting the first tidal farm of 10 MW as part of a larger build out in a selected EU market, adding the first EU site to the commercial opportunities being pursued in the Faroe Islands and North Wales. The PDA programme of the EIB is funded by the European Commission with the purpose to increase investment attractiveness of the top tier of innovative decarbonisation projects in the EU suitable for the Clean Industrial Deal that consists of a range of funding mechanisms, including the Innovation Fund. On an annual basis, a limited number of projects are offered PDA support across industries and sectors within EU.

The EIB advisory to Minesto will include capital structuring and financial modelling to facilitate fundraising. Minesto will utilise the advisory support to target financial closure of a Minesto Dragon Farm – a first-of-a-kind tidal energy array at a selected site within the EU. The Dragon Farm is anticipated as Minesto’s first project within the EU, building on years of experience from site development and tidal energy production in the Faroe Islands and in Wales.

“Being selected by renewable energy and investment experts at EIB for close collaboration on capitalization of a new Dragon Farm in the EU is of significant value to Minesto. This new project will be added as a distinct investment opportunity in parallel with the Faroe Islands build-out, creating clear synergies between the initiatives and significantly increasing the short-term expansion opportunity for our world leading tidal technology,” said Dr Martin Edlund, CEO of Minesto.

For additional information please contact
Cecilia Sernhage, Chief Communications Officer
+46 735 23 71 58
ir@minesto.com

The information in this press release is such that Minesto AB (publ) shall announce publicly according to the EU Regulation No 596/2014 on market abuse (MAR). The information was submitted for publication, through the agency of the contact person set out above, at 15:19 CET on 27 January 2026.

About the EIB Project Development Assistance programme:

Innovation Fund – Project Development Assistance

Contact
Cecilia Sernhage, Chief Communications Officer
+46 735 23 71 58
ir@minesto.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/minesto-ab/r/european-investment-bank–eib–backs-minesto-in-developing-an-investment-case-for-the-eu-s-first-tid,c4298343

The following files are available for download:

https://mb.cision.com/Main/14621/4298343/3900944.pdf

PR 260127 European Investment Bank (EIB) backs Minesto in developing investment case for EU first Tidal Energy Dragon Farm_

https://news.cision.com/minesto-ab/i/dji-0902-lq,c3505168

DJI 0902 LQ

 

Bybit, Mantle, and Byreal Partner to Extend CeDeFi Access for $MNT on Solana via Mantle Super Portal

DUBAI, UAE, Jan. 27, 2026 /PRNewswire/ — Bybit, Mantle, and Byreal today announced the launch of Mantle Super Portal, Mantle’s native cross-chain infrastructure powering seamless capital movement across ecosystems by expanding $MNT to Solana, unlocking stronger CeDeFi access. 

Bybit, Mantle, and Byreal Partner to Extend CeDeFi Access for $MNT on Solana via Mantle Super Portal
Bybit, Mantle, and Byreal Partner to Extend CeDeFi Access for $MNT on Solana via Mantle Super Portal

Through this integration, users can bridge $MNT from Ethereum to Solana via a unified interface, deploy liquidity into Solana-native DeFi markets on Byreal, and participate in trading and incentive programs on Bybit Alpha, creating a continuous flow between on-chain and exchange-based liquidity.

The launch represents a key milestone in Mantle’s multichain distribution strategy, positioning $MNT as a cross-ecosystem asset connecting Ethereum Layer 2 liquidity, Solana DeFi, and centralized exchange infrastructure, while advancing Mantle’s broader mission as the leading distribution layer to bridge traditional finance, real-world assets, and on-chain markets as one.

Mantle Super Portal: Infrastructure where Real-World & Internet Capital Market Flows

Mantle Super Portal is a foundational pillar of Mantle’s cross-chain infrastructure, purpose-built to enable fast, capital efficient, reliable, and low-friction movement of $MNT across ecosystems. 

By abstracting away complexity behind a single interface, Mantle Super Portal transforms $MNT into a natively interoperable asset, allowing users to access on-chain liquidity with consistent security and execution across networks.

With Mantle Super Portal now live, users can:

  • Bridge $MNT directly between Ethereum and Solana
  • Access Solana-native DeFi liquidity without fragmented workflows
  • Deploy capital seamlessly across on-chain and exchange-based environments

As Mantle continues to establish itself as the leading chain for real-world asset (RWA) adoption, Mantle Super Portal extends this thesis beyond a single network, enabling $MNT to move seamlessly into TradFi and DeFi capital markets where liquidity, attention, and execution converge.

$MNT Expands into Solana’s DeFi Economy via Byreal

Following the launch of Mantle Super Portal, $MNT is now live on Byreal, a Solana-native decentralized exchange incubated by Bybit. Liquidity providers can deposit $MNT into the MNT–USDC pool and earn a share of 96,000 $MNT in incentives distributed over the next three months.This integration allows $MNT to participate directly in Solana’s high-throughput DeFi environment, benefiting from low fees, fast settlement, and deep on-chain liquidity.

By extending $MNT into Solana, Mantle accelerates its role as a distribution layer that connects real-world value to the most active on-chain internet capital markets, without fragmenting liquidity or user experience.

“Byreal provides a natural home for cross-chain assets like $MNT,” said Emily Bao, Founder of Byreal and Head of Spot at Bybit. “With $MNT live on Solana, users can access competitive on-chain yield while contributing to deeper, more efficient liquidity across ecosystems.”

“Solana was built to support internet capital markets at scale: enabling price discovery for every asset on-chain, 24/7, and globally,” said Ramzy Ali, DeFi Growth Lead, Solana Foundation. “The integration through Mantle Super Portal allows users to leverage Solana’s DeFi ecosystem, connecting assets to highly composable markets designed for speed, liquidity, and global participation.”

Bybit Alpha Powers a Connected CeFi–DeFi Experience for $MNT

In parallel, Bybit Alpha will support $MNT trading and incentive programs, with full Solana deposit and withdrawal functionality enabled via Mantle Super Portal.

Users can trade $MNT on Bybit Spot and Alpha, participate in incentive campaigns and trading competitions, and benefit from transaction fee savings. Bybit’s integration creates a continuous capital flywheel that provides a centralized liquidity layer that complements on-chain activity, enabling users to combine DeFi yield with exchange-level rewards and capital efficiency.

“Bybit Alpha is designed to surface early opportunities with real utility,” said Emily Bao, Founder of Byreal and Head of Spot at Bybit. “Supporting $MNT on Solana allows users to move seamlessly between on-chain yield on Byreal and trading incentives on Bybit, all within a connected capital loop.”

Advancing Mantle’s Multichain Distribution Strategy

With Mantle Super Portal, Byreal, and Bybit Alpha working in tandem, $MNT now operates across Ethereum, Solana, and centralized venues through a single, integrated framework. This unified setup enables efficient capital mobility without compromising liquidity depth, execution quality, or user experience.

The expansion strengthens Mantle’s role as a connective layer between Layer 2 infrastructure, Solana’s DeFi markets, and CeFi platforms, extending $MNT’s utility across the full spectrum of on-chain and exchange-based activity.

“This launch represents a key step in Mantle’s multichain vision,” said Emily Bao, Key Advisor at Mantle. “By enabling $MNT to operate seamlessly across Mantle, Solana, and Bybit, we’re expanding real-world use cases and reinforcing Mantle’s role as a distribution layer for on-chain finance.”

About Mantle

Mantle is the premier distribution layer and gateway for institutions and TradFi to connect with on-chain liquidity and access real-world assets, powering how real-world finance flows.

With over $4B+ in community-owned assets, Mantle combines credibility, liquidity and scalability with institutional-grade infrastructure to support large-scale adoption. The ecosystem is anchored by $MNT within Bybit, and built out through core ecosystem projects like mETH, fBTC, MI4 and more. This is complemented by Mantle Network’s partnerships with leading issuers and protocols such as Ethena USDe, Ondo USDY, OP-Succinct and EigenLayer.

For more information about Mantle, please visit: mantle.xyz
For more social updates, please follow: Mantle Official X & Mantle Community Channel  
For media enquiries, please contact: contact@mantle.xyz 

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open, and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

About Byreal

Byreal is the ultimate liquidity layer built for real assets, delivering unmatched liquidity for users. It integrates DEX, Launch, and Vault into a unified smart routing architecture, forming a full-cycle growth engine that supports asset discovery, trading, and yield generation across multiple ecosystems.

For more information about Byreal, please visit: www.byreal.io
For updates, please follow Byreal’s social media: https://x.com/byreal_io
For media inquiries, please contact: partnerships@byreal.io

Aurzen Super Bowl Projector Deals: Big-Screen Viewing for Less

IRVINE, Calif., Jan. 27, 2026 /PRNewswire/ — Aurzen launched Super Bowl Projector Deals for viewers who want a big-screen experience without paying TV-sized prices, offering a more flexible and affordable alternative, backed by verified specs based on real-world testing.

Super Bowl has become one of the biggest viewing moments of the year for sports and entertainment fans alike. Whether you’re tuning in for the game, the halftime show, or simply gathering friends around good food, one thing is clear: watching on a small screen doesn’t quite do the moment justice.

Aurzen Roku TV Smart Projector EAZZE D1R Cube

  • U.S.: was US$249.99, now: US$169.99 at Amazon US
  • Canada: CA$195.49 (15% off) at Amazon CA starting February 2

The Roku TV D1R Cube features a built-in Roku TV experience, 1080p resolution, and Dolby Audio in a compact, easy-to-use design. It’s a great fit for indoor viewing in dim or moderate lighting, with a sealed optical engine for added durability. 

Aurzen EAZZE D1

  • U.S.: US$99.99 (33% off) at Amazon US starting February 2
  • Canada: was CA$169.99, now: CA$144.49 at Amazon CA

With a built-in smart TV and 4K support, the D1 delivers a surprisingly complete big-screen experience for under US$100, making it a solid entry-level option for casual viewing and Super Bowl watch parties. 

Aurzen EAZZE D1G

  • U.S.: US$169.99 (23% off) at Amazon US starting February 2
  • Canada: was CA$229.99, now: CA$195.49 at Amazon CA

The D1G steps things up with improved brightness and built-in Google TV, making it a better fit for living rooms where you don’t want to sit in complete darkness just to see the score.

Aurzen BOOM mini

  • U.S.: was US$349.99, now: US$229.99 at Amazon US
  • Canada: CA$288.99 (15% off) at Amazon CA starting February 2

The BOOM mini pairs Google TV with 10W Dolby Audio speakers and 500 ANSI lumens brightness for clear visuals and immersive sound. Its portable design makes it ideal for Super Bowl watch parties at home, in the backyard, or anywhere with a wall to project on.

Aurzen BOOM air

  • U.S.: was US$299.99, now: US$179.99 at Amazon US

Offering the biggest discount in the lineup, the BOOM air delivers punchy audio in a portable design without the need for extra speakers. USB-C and 65W PD power bank support enable outdoor and on-the-go viewing.

Asthma and Allergy Drug Development Is Failing Too Often–A Translational Reset Is Needed: HKEY-AIRx™1.0

BOSTON and SUZHOU, China, Jan. 27, 2026 /PRNewswire/ — HKeyBio, a preclinical CRO focused on autoimmune and allergic disease drug development, today announced a translational preclinical strategy, HKEY-AIRxTM1.0  designed to address one of the most persistent problems facing biotech leadership: why so many asthma and allergy programs with strong preclinical data fail to deliver meaningful clinical outcomes.

Over the past decade, asthma and allergic airway diseases have attracted substantial investment, the emergence of advanced biologics, and increasingly sophisticated targets. Yet for biotech and biopharma decision makers, the outcome is familiar—high attrition, limited differentiation, and late-stage disappointment. In many cases, the root cause is not target selection, but how preclinical evidence is generated and interpreted.

“Too many asthma and allergy programs enter the clinic with data that answer academic questions rather than development questions,” said HKeyBio’s scientific leadership team. “From an executive perspective, the real risk lies in making early decisions based on models that do not reflect disease endotypes, clinical positioning, or patient heterogeneity.”

From Scientific Signals to Executive Decisions

HKeyBio’s asthma and allergy strategy, HKEY-AIRxTM1.0 is built explicitly to support executive-level decision-making, not just experimental readouts. The framework aligns:

  • Disease endotypes and patient heterogeneity
  • Drug mechanism and modality differentiation
  • Preclinical model choice and translational endpoints

This approach enables biotech leadership teams to evaluate whether a program is likely to deliver clinically meaningful benefit in a defined patient population—before committing to costly IND and clinical development milestones.

Rather than relying on single-model efficacy narratives, HKEY-AIRxTM1.0 applies a portfolio-based strategy that reflects the biological and clinical complexity of asthma and allergic airway diseases, including T2-high, non-T2, and innate immune–driven mechanisms, as well as acute inflammation versus chronic airway remodeling.

De-Risking Capital Allocation in Asthma and Allergy Pipelines

For biotech and biopharma leaders, asthma and allergy programs often represent a disproportionate allocation of capital relative to their probability of success. HKeyBio’s integrated preclinical ecosystem, HKEY-AIRxTM1.0 is designed to reduce that imbalance by generating data that directly inform:

  • Go/no-go decisions
  • Asset differentiation versus the Standard of Care
  • IND-enabling strategies and early clinical design
  • Portfolio prioritization across multiple indications

By emphasizing translational endpoints and biomarker strategies, HKeyBio helps clients move beyond the question of whether a compound “works” in a model to whether it is investable, defensible, and clinically actionable.

A Strategic Partner, Not Just a Service Provider

HKeyBio positions itself as a strategic preclinical partner for biotech and biopharma companies developing next-generation therapies for asthma and allergic diseases. The company supports programs spanning small molecules, biologics, and multispecific or combination approaches, with an emphasis on aligning preclinical evidence with regulatory and clinical realities.

To ensure seamless collaboration across regions, HKeyBio operates on a dedicated, co-located team model for strategic projects, providing U.S.-based clients with direct points of contact during their business hours for real-time communication and project oversight. Our operational protocols ensure data integrity, process transparency, and rigorous compliance. We uphold the highest standards of confidentiality and intellectual property protection, with clear IP frameworks defined at project inception. These foundational practices are built on ISO 9001 certification, adherence to GLP principles, AAALAC accreditation, and are validated by over 500 successful IND submissions. This is what enables us to deliver not just data, but the clarity and confidence needed for decisive capital allocation. 

“Our clients are not looking for more data—they are looking for clarity,” the HKeyBio team added. “Our role is to help leadership teams make earlier, better-informed decisions that protect both patients and capital.”

About HKeyBio

HKeyBio is a globally leading preclinical CRO specializing in research and development in the fields of autoimmune and allergic diseases. The company boasts a core technical team with over 20 years of experience, possessing deep expertise and extensive project experience in novel drug development for autoimmune diseases.

HKeyBio has successfully supported more than 500 Investigational New Drug (IND) submissions worldwide. Certified under ISO9001 quality management standards and AAALAC international accreditation, the company has established an efficient and reliable R&D and regulatory submission system. HKeyBio is dedicated to helping partners navigate the complex challenges of autoimmune drug development and IND submissions, providing professional, compliant, and efficient one-stop solutions to accelerate new drugs into clinical trials and ultimately benefit patients worldwide.

To discuss how HKeyBio’s translational strategies and dedicated partnership model can de-risk your asthma and allergy development program, please visit www.hkeybio.com or contact our team at tech@hkeybio.com.

 

FutureMain Bolsters Global Industrial AI Competitiveness with NPU-Based Time-Series AI Project

SEOUL, South Korea, Jan. 27, 2026 /PRNewswire/ — FutureMain Co., Ltd., a specialized industrial AI company focused on equipment diagnostics and predictive maintenance, announced that it is playing a pivotal role in a next-generation intelligent semiconductor R&D project centered on the development of integrated artificial intelligence software for processing time-series big data on NPU-based environments.

The project is part of the Next-Generation Intelligent Semiconductor Technology Development (Design) Program, within the Intelligent Semiconductor Software category. Titled “Development of an Integrated AI Processing Software Package for NPU-Based Time-Series Big Data,” the initiative spans three years and nine months, from April 2023 through December 2026.

The consortium is led by Mobilint Co., Ltd., with FutureMain, Raonroad Co., Ltd., and KAIST (Korea Advanced Institute of Science and Technology) participating as co-research institutions.

The project focuses on developing an integrated software package designed to process large-scale time-series data generated in smart factory and smart city environments using CNN- and RNN-based AI models, optimized for both edge and server NPUs. The software package integrates time-series data management, security, and visualization functions, along with NPU SDK components including compilers, quantizers, and runtime libraries.

To validate real-world applicability, two types of NPU prototype boards—an Edge NPU board and a Server NPU board—are being developed and tested. The consortium aims to implement and verify demonstration applications in both smart factory and smart city domains, with active development and validation currently underway.

In the smart factory domain, the project includes the development of software for equipment and process data–based condition monitoring, anomaly detection, automated diagnostics, and visualization. In the smart city domain, efforts focus on traffic time-series data collection, average section speed prediction, application of traffic digital twin technologies, and pilot demonstrations in collaboration with local governments.

As a co-research institution responsible for the smart factory domain, FutureMain is leading research and development related to AI and security technologies based on equipment and process data. The company is responsible for defining and classifying equipment and process data, designing data collection methodologies, and developing technologies across the time-series data lifecycle. FutureMain is also overseeing training module requirement analysis, algorithm management architecture design, data anonymization and secure storage modules applicable to both edge and server environments, and the deployment of server-based AI algorithms for anomaly detection in industrial equipment and processes.

A FutureMain representative stated, “Through this project, we are advancing AI and security technologies that enable efficient processing of smart factory time-series data in NPU-based environments. We will continue our R&D efforts to ensure that anomaly detection technologies based on equipment and process data can be effectively applied in real industrial settings.”

Building on the NPU-based time-series big data AI processing technologies secured through this project, FutureMain plans to further enhance technologies applicable across a wide range of industrial fields, including smart factories. In particular, the company will continue to expand the real-world applicability of AI-based anomaly detection and security technologies for equipment and process data progressively.

FutureMain is also exploring opportunities for global market expansion. With growing interest in NPU-based AI processing technologies—particularly in the United States and other global markets—the company aims to strengthen the competitiveness of its industrial AI solutions by leveraging the technological capabilities secured through this project.

 

Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies

CAMBRIDGE, Mass., Jan. 27, 2026 /PRNewswire/ — Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its subsidiary Shanghai Qilu Pharmaceutical Research Center, today announced a strategic partnership on innovative drug development, leveraging Insilico’s proprietary Pharma.AI platform to jointly develop small molecule inhibitors, focusing on specific targets for cardiometabolic disease management.

According to the agreement, Insilico Medicine will utilize its proprietary Pharma.AI platform to focus on the design and optimization of novel small molecules for treating metabolic diseases, while Qilu Pharmaceutical Group will be responsible for subsequent development and commercialization procedures. The total contract value approaches $120 million, including development and commercialization milestone payments, as well as single-digit royalties based on net sales.

Weikang Tao, PhD, Board Member, Group VP & Head of Global R&D, Qilu Pharmaceutical Group said, “As a leading pharmaceutical company in China, Qilu has always attached great importance to the quick advancement of AI technology, in particular, the application of AI in drug R&D and its potential. Insilico is a well-known biotech in AI-powered drug R&D with advanced AI technology and application capabilities. This collaboration marks a deepening of our partnership, evolving from initial software licensing to in-depth, R&D collaboration. We look forward to the smooth progress of this innovative drug discovery and development project through the synergy of Qilu’s extensive R&D experience and capabilities and Insilico’s advanced AI platform and expertise, thereby to address unmet medical needs and to bring new hope to patients worldwide.”

Alex Zhavoronkov, PhD, Founder and Chief Executive Officer, Chief Business Officer of Insilico Medicine said, “We are pleased to see Insilico Medicine and Qilu Pharmaceutical further deepen their strategic collaboration driven by generative AI. Recently, Insilico Medicine unveiled its proprietary cardiometabolic portfolio at the BIO-Europe conference, covering 8 drug candidates ranging from hit to IND-enabling stage, all driven by Pharma.AI in their development process. I believe that strategies targeting cardiometabolic diseases have the potential to generate the first drugs to achieve large-scale healthspan extension, and I look forward to AI technology accelerating innovation in the field and maximizing potential.”

Based on drug discovery and development, software solution licensing, and innovative expansion beyond drug development, Insilico Medicine continues to validate its diversified business model, securing software licensing agreements with 13 of the world’s top 20 multinational pharmaceutical companies, establishing research collaborations with upfront payments of tens of millions of dollars with Fosun Pharma and Sanofi; and reaching pipeline out-licensing deals with Exelixis and Menarini Group, with total transaction values exceeding $2 billion. Notably, Qilu Pharmaceutical first started using PandaOmics in 2021, thus leading to the near $120 million collaboration today, which will further deepen the empowering role of the artificial intelligence platform and drive innovative therapy development with even higher efficiency.

In 2016, Insilico first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal, which laid the foundation for the commercially available Pharma.AI platform. Since then, Insilico keeps integrating technical breakthroughs into Pharma.AI platform, which is currently a generative AI-powered solution spanning across biology, chemistry, medicine development and science research. Powered by Pharma.AI, Insilico has nominated 22 developmental/preclinical candidates (DC/PCC) in its comprehensive portfolio of over 30 assets since 2021, with the most advanced candidate Rentosertib achieving positive results in Phase IIa clinical trials, achieving the first proof-of-concept for AI-driven drug development in the clinical stage.

About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.

By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com 

About Qilu Pharmaceutical
Qilu Pharmaceutical is a pharmaceutical enterprise group dedicated to the well-being of families and humanity, driven by innovation, and guided by a global vision. The company operates 11 major production bases spanning 6.1 square kilometers and employs over 36,000 people. In 2024, it was ranked third in the “China Pharmaceutical Industry Top 100.”

Upholding the core values of “Great Medicine for the Benefit of Mankind,” the group is dedicated to meeting the public’s needs for a healthy and better life by delivering high-quality, trustworthy medicines worldwide. To date, it has launched more than 320 products, including 79 that were first-to-market or exclusive in China. Its products are exported to over 100 countries and regions, benefiting approximately 1.5 billion patients annually.

Committed to “innovation from the heart” and aligned with the forefront of global science and technology, the group has established six integrated R&D platforms across China and the U.S., building a globally influential product pipeline. The pipeline includes nearly 300 branded generic drugs and over 20 biosimilars under development, with more than 80 innovative medicines currently in various stages of clinical trials.

 

Antigravity Updates A1 with Virtual Flight Simulator and Announces 15% Off US Sale

The world’s first 8K 360 drone expands US retail availability to Amazon following breakout success at CES.

LOS ANGELES, Jan. 27, 2026 /PRNewswire/ — Antigravity will announce a major feature update for the Antigravity A1, introducing a built-in Flight Simulator to help new pilots master the skies. To celebrate the update, the brand is offering a 15% discount on all A1 bundles globally from January 27 to February 9.

Antigravity A1, is currently 15% off all bundles
Antigravity A1, is currently 15% off all bundles

Following a breakout performance at CES, the A1 has seen impressive sales momentum, becoming a top seller at Best Buy and official channels. Antigravity is also proud to announce that the A1 is now fully available on Amazon, further expanding access for US customers.

New Feature: Flight Simulator
To welcome new pilots to the A1 experience, Antigravity has released the Flight Simulator. Accessible directly inside the Vision Goggles, this feature creates a complete virtual flying environment that faithfully replicates the A1’s physics and handling, allowing those new to flight to simulate before taking to the skies for real.

The simulator offers a low-risk entry, allowing new pilots to build muscle memory without risking a crash. While at home preparing for the next shoot, or waiting for weather to clear, the simulator stands as the perfect choice to hone flight skills in the real world.

Pilots can officially update and experience this new feature on January 29th.

Widely Available and Fully Compliant
With its expansion to Amazon, the A1 remains one of the few premium drones widely available across major US retailers. Antigravity confirms that all A1 models remain fully compliant following the recent FCC “Covered List” update. The import, distribution, sale, and operation of the A1 continue without restriction, ensuring that US customers can fly with total peace of mind.

Limited Time Offer: 15% Off A1
To celebrate Antigravity’s latest update, the brand is offering 15% off all three A1 bundles (Standard, Explorer, and Infinity) globally from Jan 27 to Feb 9. For more information, visit antigravity.tech.

About Antigravity
Antigravity is a consumer drone company reimagining how people experience flight. Incubated by Insta360 and third parties, Antigravity uses the latest 360 technology to build powerful drones that are immersive and easy for anyone to fly. The company is pioneering a new generation of aerial explorers and storytellers by making drone flight more expressive and inclusive. Built by a global team of engineers, designers, and creators, Antigravity released its first drone in late 2025.

Antigravity on Social Media
YouTube
Instagram
Facebook
X (formerly Twitter)
TikTok
LinkedIn

¹ The term “world’s first” refers to the fact that, as of July 28, 2025, Antigravity has announced the market’s first 8K all-in-one 360 drone. It captures high-quality 360 video directly without the need for an external 360 camera attachment. The drone features a built-in 360 camera, supports real-time data transmission, and allows users to adjust shooting parameters on the fly.